Revenue from the hi-tech segment, which has been under pressure lately, fell 3.1% quarter-on-quarter as a couple of large telecom and medtech (medical device engineering) deals slipped into early Q2FY27. LTTS expects hi-tech to return to growth in Q2FY27. If it does, it could be a re-rating trigger for the stock, which is down 20% so far in 2026.
About The Author
